At Neurophth, we walk from obstacle to obstacle without loss of enthusiasm.                        
在纽福斯公司，我们是从一个障碍走向另一个障碍而不丧失热情。

We are China’s first gene therapy company for ophthalmic diseases. Our mission is building a brighter future for patients by innovative gene therapies.  

Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and USA, we are striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally.  We leverage our AAV and CMC platforms to regain vision in patients suffering from Leber’s hereditary optic neuropathy (LHON), autosomal dominant optic atrophy, vascular retinopathy (wAMD, DME, etc), optic neuropathy (glaucoma, etc) and other genetic diseases. Our most advanced investigational candidate, NR082 (rAAV2-ND4), in development for the treatment of LHON associated with ND4 mutation using a single administration through less invasive intravitreal injection, has received orphan disease designations in the U.S. 

We are always seeking highly motivated and talented individuals with diverse experiences, abilities and interests who are seeking to inspire the world and help patients to restore vision to join us on our journey. To learn more about Neurophth and our open positions, visit www.neurophth.com.

Sequoia Capital China

Northern Light Venture Capital

InnoVision Capital

Grand Mount Capital

Guofang Capital

Harvest Capital

Sunshine Insurance Group

CMB International Capital Corporation

CMG-SDIC Capital Management

Neurophth Therapeutics / 纽福斯生物科技有限公司

Biopharmaceutical company developing therapies for metabolic & orphan diseases

Rezolute

Developer of pharmaceutical products for ophthalmic diseases

EyePoint Pharmaceuticals

Neurophth is a biotechnology company specializing in the development of gene therapies for ophthalmic diseases. Their focus is on creating innovative treatments to restore vision and improve the quality of life for patients with visual impairments.

Neurophth

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 16, 2024 9:26 AM	4ac484c9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	2dc2c6ab
crunchbase profile	general	Nov 18, 2024 2:22 PM	f680f4f0
li profile	general	May 16, 2024 9:26 AM	c88a245c
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NEUROPHTH

Neurophth